Tianzhi Pharmaceutical

Tianzhi Pharmaceutical is a China-based biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs, primarily focused on dermatological and inflammatory conditions. The company is best known for developing Benvitimod (marketed under the brand name Xinditai), a first-in-class, non-steroidal aryl hydrocarbon receptor (AhR) modulator approved in China for the topical treatment of plaque psoriasis. This development represents a significant milestone in Chinese drug innovation, as Benvitimod was one of the first internally developed novel drugs to receive NMPA approval in the dermatology space. Tianzhi Pharmaceutical maintains its own manufacturing facilities and is currently expanding its clinical pipeline to include indications such as atopic dermatitis and other immune-mediated disorders.